Approaches for Scalable Manufacturing of Engineered B-Cell Medicines: A New Class of Cellular Medicines
Time: 1:00 pm
day: Day Two - Track B PM
Details:
- Be Biopharma has developed a new class of cellular medicines – Engineered B-Cell Medicines (BCMs) – with the potential to be durable, allogeneic, redosable and administered without pre-conditioning
- B-Cell Medicines (BCMs) are produced with ex vivo precision engineering of B-cells using CRISPR/Cas9 and homology directed repair-mediated transgene insertion followed by ex vivo differentiation towards plasma cell lineage
- Process development, optimization and scalable manufacturing strategies will be discussed
